Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 65,359 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 65,359 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $0.47, for a total value of $30,718.73. Following the transaction, the director now owns 4,012,320 shares of the company’s stock, valued at approximately $1,885,790.40. This trade represents a 1.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

Shares of IVVD stock opened at $0.45 on Tuesday. The company has a fifty day moving average price of $0.82 and a two-hundred day moving average price of $1.05. Invivyd, Inc. has a one year low of $0.45 and a one year high of $5.20. The stock has a market cap of $53.89 million, a P/E ratio of -0.23 and a beta of 0.53.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC increased its position in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares during the last quarter. State Street Corp increased its holdings in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in Invivyd in the 3rd quarter valued at $27,000. Cubist Systematic Strategies LLC lifted its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Invivyd during the 2nd quarter valued at $115,000. 70.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

IVVD has been the subject of several research reports. Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright decreased their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.